Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive crawled date : 2021 - 05 - 21 save search
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) plus Yervoy (ipilimumab) for Treatment of Mismatch Repair Deficient
Published: 2021-05-21 (Crawled : 23:00) - biospace.com/
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: 0.36%
H: 1.01%
C: -0.28%
treatment positive chmp nivolumab
Annovis Bio Announces Positive Phase 2 Data - ANVS401 Improves Cognition in Alzheimer's Disease - Patients' Cognition Improved 3.3 Points on ADAS-Cog11
Published: 2021-05-21 (Crawled : 18:00) - biospace.com/
ANVS | $12.74 92
|
Health Technology
|
| O: 39.81%
H: 165.43%
C: 62.56%
disease alzheimer phase 2 positive alzheimer’s alzheimer's disease alzheimer's anvs401
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for Setmelanotide for Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR DeficiencyEuropean Commission decision anticipated in July
Published: 2021-05-21 (Crawled : 17:00) - biospace.com/
RYTM 4 | $39.71 -0.73% -0.73% 0
|
Health Technology
|
| O: 1.17%
H: 3.83%
C: -0.28%
treatment obesity europe positive setmelanotide chmp
Athenex Announces Klisyri® (tirbanibulin) Receives Positive CHMP Opinion from the European Medicines Agency (EMA) for the Treatment of Actinic Keratosis of the Face or ScalpEuropean Commission Decision Anticipated by July 2021
Published: 2021-05-21 (Crawled : 16:00) - biospace.com/
ATNX | $0.2031 -7.78% 1.9M
|
Health Technology
|
| O: 1.04%
H: 1.85%
C: -1.85%
treatment actinic keratosis europe positive tirbanibulin chmp ema
Almirall receives positive CHMP opinion for Klisyri®▼ (tirbanibulin), an innovative topical treatment for actinic keratosis
Published: 2021-05-21 (Crawled : 14:00) - prnewswire.com
ATNX | $0.2031 -7.78% 1.9M
|
Health Technology
|
| O: 1.04%
H: 1.85%
C: -1.85%
treatment actinic keratosis positive tirbanibulin chmp
Halozyme Announces Janssen Receives Two Positive CHMP Opinions for DARZALEX® (daratumumab) Subcutaneous Formulation Utilizing ENHANZE®
Published: 2021-05-21 (Crawled : 14:00) - halozyme.com
HALO 4 | $39.12 0.39% 0.32% 4
|
Health Technology
|
| O: 1.45%
H: 0.28%
C: -2.54%
positive chmp
Athenex Announces Klisyri® (tirbanibulin) Receives Positive CHMP Opinion from the European Medicines Agency (EMA) for the Treatment of Actinic Keratosis of the Face or Scalp
Published: 2021-05-21 (Crawled : 14:00) - globenewswire.com
ATNX | $0.2031 -7.78% 1.9M
|
Health Technology
|
| O: 1.04%
H: 1.85%
C: -1.85%
treatment actinic keratosis europe positive tirbanibulin chmp ema
CORRECTION -- EMA Issues Positive Scientific Opinion on GSK and Vir Biotechnology’s Sotrovimab For the Early Treatment of COVID-19
Published: 2021-05-21 (Crawled : 14:00) - globenewswire.com
GSK | News | $40.86 -0.92% 0.91% 11K
|
Health Technology
|
| O: -0.26%
H: 0.26%
C: -0.21%
LLY | News | $732.2 -1.81% -0.71% 8K
|
Health Technology
|
| O: 0.24%
H: 0.96%
C: -0.06%
VIR | $7.97 -0.87% 8.5K
|
Health Technology
|
| O: 1.75%
H: 0.13%
C: -1.44%
SNY | News | $46.61 -2.27% -2.21% 220K
|
Health Technology
|
| O: -0.43%
H: 0.2%
C: 0.02%
covid treatment positive biotech technology iot ema
Genmab Announces that Janssen has Received Positive CHMP Opinion Recommending DARZALEX® (daratumumab) Subcutaneous (SC) Formulation for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
Published: 2021-05-21 (Crawled : 13:15) - globenewswire.com
JNJ | News | $148.53 -0.69% 0.11% 67K
|
Health Technology
|
| O: 0.15%
H: 0.82%
C: -0.22%
GMAB | News | $28.47 -0.32% -0.32% 420
|
Health Technology
|
| O: 1.34%
H: 0.71%
C: 0.13%
positive chmp als
bluebird bio Receives Positive CHMP Opinion for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age with Early Cerebral Adrenoleukodystrophy (CALD)
Published: 2021-05-21 (Crawled : 13:00) - biospace.com/
BLUE | $0.885 -4.11% 740K
|
Health Technology
|
| O: 0.98%
H: 2.74%
C: 1.71%
gene therapy positive therapy gene therapies chmp
Myovant Sciences Receives Positive CHMP Opinion for RYEQO® (Relugolix Combination Tablet) for the Treatment of Women With Uterine Fibroids
Published: 2021-05-21 (Crawled : 13:00) - globenewswire.com
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: 1.71%
H: 4.69%
C: 1.59%
treatment positive women chmp
Albireo Receives Positive CHMP Opinion for Bylvay™ (odevixibat) for Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)
Published: 2021-05-21 (Crawled : 13:00) - globenewswire.com
ALBO | $44.15 -0.23% 0.39% 1.2M
|
Health Technology
|
| O: 7.57%
H: 0.0%
C: -2.16%
treatment positive chmp
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for Setmelanotide for Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR Deficiency
Published: 2021-05-21 (Crawled : 13:00) - globenewswire.com
RYTM 4 | $39.71 -0.73% -0.73% 0
|
Health Technology
|
| O: 1.17%
H: 3.83%
C: -0.28%
treatment obesity positive setmelanotide chmp
EMA Issues Positive Scientific Opinion on GSK and Vir Biotechnology’s Sotrovimab For the Early Treatment of COVID-19
Published: 2021-05-21 (Crawled : 12:15) - globenewswire.com
GSK | News | $40.86 -0.92% 0.91% 11K
|
Health Technology
|
| O: -0.26%
H: 0.26%
C: -0.21%
LLY | News | $732.2 -1.81% -0.71% 8K
|
Health Technology
|
| O: 0.24%
H: 0.96%
C: -0.06%
VIR | $7.97 -0.87% 8.5K
|
Health Technology
|
| O: 1.75%
H: 0.13%
C: -1.44%
SNY | News | $46.61 -2.27% -2.21% 220K
|
Health Technology
|
| O: -0.43%
H: 0.2%
C: 0.02%
covid treatment positive biotech technology iot ema
BeiGene Announces Positive Topline Results from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Published: 2021-05-21 (Crawled : 12:00) - biospace.com/
BGNE | $148.04 2.72% 24K
|
Health Technology
|
| O: 0.1%
H: 1.6%
C: 0.88%
treatment positive therapy results cancer topline phase 3 trial
Gainers vs Losers
| 50% | 50% |
Top 10 Gainers
CSSE 4 | $0.299 96.32% 7M
|
Consumer Services
BRFH 4 | $1.99 80.91% 13M
|
Manufacturing
BOF | $1.915 63.68% 620K
|
AMST | $3.13 56.5% 500K
|
Technology Services
ACON | $0.3595 24.83% 3.5M
|
n/a
CDTX | News | $14.57 18.55% 330K
|
Health Technology
ULBI M | $10.12 15.92% 120K
|
Producer Manufacturing
LRHC | $1.79 11.88% 3K
|
n/a
AIXI | $1.34 8.94% 42K
|
n/a
TRU | $74.475 8.44% 100K
|
Technology Services
Your saved searches
Save your searches and get alerts when important news are released.